Zimmer Biomet Holdings, Inc. (ZBH)

Several events have impacted Zimmer Biomet's stock price over the past six months. The company reported Q2 2025 earnings with a 7.0% increase in net sales and updated its full-year revenue growth guidance. Zimmer Biomet completed the acquisition of Monogram Technologies and launched new foot and ankle solutions. The company received FDA Breakthrough Designation for its iodine-treated total hip replacement system. Q3 2025 earnings were announced with a 9.7% increase in net sales, beating consensus estimates. The company received FDA clearance for an enhanced version of its ROSA® Knee Robotic Technology and collaborated with OneStep to provide enhanced mobility data. Analyst ratings varied, with JPMorgan maintaining a 'Neutral' rating, Bernstein raising its price target, and UBS lowering its price target. The CEO issued cautious remarks on the company's 2026 outlook, leading to a session low for the shares. Several executives engaged in insider selling activity. The company is scheduled to release its Q4 2025 earnings on February 10, 2026. The stock has recently been trading at the lower end of its 52-week range.

Zimmer Biomet's products and services experience demand seasonality. The first and fourth quarters typically benefit from additional selling days. The second and third quarters often face headwinds, with the third quarter generally representing the low point for both gross and operating margins due to seasonal trends. The fourth quarter is then expected to show significant sequential improvement and deliver the highest margins for the year.

Zimmer Biomet Holdings, Inc. is a global medical technology company specializing in musculoskeletal healthcare solutions, operating within the Health Technology sector and the Medical Specialties industry. Its products include orthopedic reconstructive products, sports medicine, biologics, extremities, trauma products, spine, craniomaxillofacial, thoracic products, office-based technologies, dental implants, related surgical products, and advanced surgical robots.

Zimmer Biomet has a significant global presence, serving healthcare professionals and patients in over 100 countries across developed and emerging markets. The company's operations are segmented into three main geographical regions: Americas, Europe/Middle East/Africa (EMEA), and Asia Pacific. As of the end of 2024, net sales were distributed with 57.8% from the United States, 4.7% from other Americas, 22% from Europe/Middle East/Africa, and 15.5% from Asia/Pacific.

In the past year, an investigation by Hagens Berman over alleged emerging market failures and "inconsistent" execution could impact Zimmer Biomet's brand reputation, as reported on February 3, 2026.

Zimmer Biomet Holdings, Inc. is primarily owned by institutional investors, who hold approximately 99.6% of the shares. Major institutional owners include The Vanguard Group, Inc., Dodge & Cox, BlackRock, Inc., T. Rowe Price Group, Inc., State Street Global Advisors, Inc., Capital Research and Management Company, Geode Capital Management, LLC, American Century Investment Management Inc., Harris Associates L.P., and Franklin Resources, Inc. Mutual Funds & ETFs collectively hold 65.36% of the common stock, while other institutional investors hold 33.94%. Individual insiders hold a smaller percentage, around 0.135% of the shares.